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Introduction 
 
Telomeres are repetitive non-coding DNA se-
quences at the ends of chromosomes that pro-
vide protection against chromosomal instability. 
Telomeres shorten with cell division and at a 
critical length eventually signal cellular senes-
cence. Telomerase, an enzyme which maintains 
telomere length, is typically inactive in somatic 
cells but is expressed in 90% of human tumors, 
resulting in cellular immortalization [1, 2]. Te-
lomere length and stability are likely influenced 
by variation in telomere maintenance genes 
including TERT (which partially encodes telom-
erase), TRF1, TRF2, TNKS, and POT1 [3].  
 
Previous studies have shown that telomere 
length is predictive of overall mortality [4] as 
well as cancer mortality [5-7]. The majority of 
inter-individual variation in telomere length ap-
pears to be genetically determined [8, 9] and 
genome wide association studies (GWAS) and 
candidate gene studies have highlighted the 
importance of genetic variation in the TERT lo-
cus in relation to ovarian cancer risk as well as 
other cancers [10-18]. Furthermore, this locus 
has recently emerged as a predictor of survival 
and prognosis in lung cancer [19] and glioma 
[20], but has not been examined in relation to 
ovarian cancer survival. The aim of this study 
was to investigate whether SNPs in five te-
lomere maintenance genes were associated 
with survival among women diagnosed with in-
vasive epithelial ovarian cancer in the popula-
tion-based New England Case-Control Study. We 
also examined whether the associations be-
tween these exposures and survival differed by 
histologic subtype, age, smoking, body mass 
index (BMI), estimated lifetime number of ovula-
tory cycles, and among those receiving chemo-
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therapy. Finally we examined whether these 
exposures were associated with time to relapse 
and chemo-refractory disease.  
 
Materials and methods 
 
Study population 
 
This study includes participants from the popu-
lation-based New England Case-Control Study 
(NECC) of ovarian cancer diagnosed with inva-
sive epithelial ovarian cancer from 1992-2008. 
Data for these analyses come from three enroll-
ment phases (1992-1997, 1998-2002, 2003-
2008) corresponding to three funding periods. 
Details regarding enrollment are described else-
where [21, 22]. Briefly, 3957 women residing in 
eastern Massachusetts or New Hampshire with 
a diagnosis of incident ovarian cancer were 
identified through hospital tumor boards and 
statewide cancer registries. Of these 3083 were 
eligible and 2203 (71%) agreed to participate. 
Controls (n=2100) were not included in this 
analysis. All study participants were interviewed 
at the time of enrollment about known and sus-
pected ovarian cancer risk factors. To avoid the 
possible impact of pre-clinical disease on expo-
sure status, cases were asked about exposures 
that occurred at least one-year before diagno-
sis. Over 95% of the participants provided a 
blood specimen. In a subset of the cases 
(n=793) who were diagnosed at Brigham and 
Women’s Hospital or Massachusetts General 
Hospital, we abstracted data on chemotherapy 
and residual disease from medical records. 
Date of death was identified through the Social 
Security Death Index. This study was approved 
by the Institutional Review Boards of Brigham 
and Women’s Hospital and Dartmouth Medical 
School; each participant provided a signed in-
formed consent.  
 
SNP selection and genotyping 
 
We genotyped 40 tagging SNPs in five genes 
involved in telomere maintenance (TERT, POT1, 
TNKS, TRF1, and TRF2) identified through pub-
licly available data from the HapMap Phase II 
(www.hapmap.org) as described previously[18]. 
Duplicate samples were in 100% concordance. 
DNA was extracted from buffy coat samples 
using QIAmp (Qiagen, Chatsworth, CA); due to 
limited availability of genomic DNA, samples 
were amplified using Genomiphi (GE Health-
care, Piscataway, NJ). All genotyping was per-
formed at the Dana-Farber/Harvard Cancer 
Center (DF/HCC) High Throughput Polymor-
phism Core, an affiliate of the Partners Health-
Care Center for Personalized Genetic Medicine. 
First, we genotyped 39 SNPs on samples col-
lected between 1992-2002 (n=881) using 5′ 
nuclease assays (Taqman®) on the Applied Bio-
systems Prism 7900HT Sequence Detection 
System (Applied Biosystems, Foster City, Califor-
nia). Then, we genotyped 32 SNPs on samples 
collected between 2003-2008 (n=663) using 
the Applied Biosystems Taqman OpenArray 
genotyping platform. Taqman® primers, probes, 
and conditions for genotyping assays are avail-
able upon request. Replicate samples 
(approximately 10%) were included for quality 
control and had 100% concordance. Genotyping 
was performed by laboratory personnel blinded 
to quality control replicates. Over 95% of the 
samples were successfully genotyped for each 
polymorphism.  
 
Statistical analysis 
 
Cases were excluded if their primary tumor was 
of a borderline histology (n=426) or was non-
epithelial (n=127), if they did not have genotype 
data (n=105), had an implausible date of death 
(n=1), or were non-white (n=63) because we 
observed that several SNP frequencies varied 
by race. Cox proportional hazard models with 
time since diagnosis in months as the time 
scale were used to calculate hazard ratios (HRs) 
and 95% confidence intervals (95% CIs) for the 
association between each SNP and death. Par-
ticipants contributed person-time from the date 
of ovarian cancer diagnosis until death, or the 
date survival status was last updated (most 
recent update May 2012). Among 793 invasive 
cases with abstracted clinical data, 488 had 
information on dates of chemotherapy, surgery, 
and relapse. For these cases, we evaluated the 
association between each SNP and time to re-
lapse after first-line chemotherapy using Cox 
proportional hazard models. Participants in 
these analyses contributed person-time from 
the date of end of first-line chemotherapy until 
relapse, or date of last follow-up. Logistic regres-
sion was used to evaluate the association be-
tween each SNP and chemo-refractory disease. 
Chemo-refractory disease was defined in two 
ways: relapse within six months of completing 
first-line chemotherapy or relapse within six 
months after primary debulking surgery. Multi-
variate models were adjusted for age 
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(continuous), enrollment phase (1992-1997, 
1998-2002, 2003-2008), study center 
(Massachusetts, New Hampshire), tubal ligation 
(yes, no), smoking (never smoker, former/
current smoker where former/current smokers 
are individuals who have smoked 100 or more 
cigarettes during their lifetime), oral contracep-
tive use (never, <2 years, 2-5 years, 5+ years), 
hormone replacement therapy (ever use, never), 
and menopausal status (premenopausal/
dubious, postmenopausal). Additional multivari-
able models were adjusted for the following 
clinical characteristics: histologic subtype 
(serous, mucinous, endometrioid, clear cell, 
other/undifferentiated) and grade (1/2, 3, miss-
ing/unknown/ indeterminable). 
 
There were no SNPs out of Hardy-Weinberg 
Equilibrium at p<0.001. SNP associations were 
evaluated using a log-additive model where the 
hazard ratio represents the incremental in-
crease or decrease in risk of death or risk of 
relapse with each additional allele. Variables 
evaluated for effect modification included those 
potentially associated with ovarian cancer sur-
vival and/or thought to influence telomere 
length: histologic subtype, age, smoking, BMI, 
and estimated lifetime number of ovulatory cy-
cles. Histologic subtypes were categorized into 
serous, mucinous, endometrioid, clear cell, and 
other/undifferentiated. Age was dichotomized 
into <50 years and ≥ 50 years; smoking was 
classified into never smoker and past/current 
smoker; BMI was categorized into normal 
weight (<25 kg/m2) and overweight/obese (≥25 
kg/m2); and ovulatory cycles was divided into 
two categories based on the median value. All 
tests for interaction were performed using a 
likelihood ratio test to compare models with and 
without the interaction terms.  
 
We conducted sensitivity analyses stratifying by 
time between blood draw and diagnosis; specifi-
cally, we calculated estimates for the associa-
tion between each SNP and death for cases 
with blood draw within 154 days of diagnosis 
(lowest quartile) versus more than 154 days 
after diagnosis. In addition, we conducted a 
sensitivity analyses restricting to those with 
grade 3 cancer and serous cases, the largest 
histologic subgroup. Among the subset of cases 
with more detailed medical record data we con-
ducted a sensitivity analyses among cases who 
received chemotherapy as well as adjusting for 
debulking status (optimally debulked, not opti-
mally debulked).  
 
To evaluate gene level associations, we em-
ployed a principal components approach de-
scribed previously by Gauderman and col-
leagues that accounts for linkage disequilibrium 
between SNPs[23]. Briefly, we estimated the 
combinations of SNPs, grouped as principal 
components (PCs) that represent the genetic 
variation across the gene. Then, we included 
the fewest number of PCs that together de-
scribe at least 80% of the variation in a model 
with mortality as the outcome. Using a likeli-
hood ratio test, we compared models with and 
without selected principal components to deter-
mine the association between the gene of inter-
est and ovarian cancer risk. To account for mul-
tiple testing we used a threshold of p<0.001 for 
significance for all analyses.   
 
Results 
 
Overall our study included 1480 cases of inva-
sive epithelial ovarian cancer with 710 deaths 
from 1992-2012. Participant characteristics are 
described in Table 1. The mean (±SD) age at 
study entry was 55.8 years (±11.0) and the 
mean follow-up time was 6.3 years (±5.0). Sev-
enty three percent of deaths were among se-
rous (n=515), 10.6% clear cell (n=75), 7.9% 
endometrioid (n=56), 2.3% were among muci-
nous (n=16), and 6.8% other/undifferentiated 
(n=48).  
 
We genotyped 40 tagging SNPs in five telomere 
maintenance genes (TERT, TRF2, TRF1, TNKS, 
and POT1). Though we observed some sugges-
tive associations, none met our significance 
threshold of 0.001. TERT SNP rs6882077 had 
a covariate-adjusted HR (95% CI) of death of 
3.49 (1.11-11.02) for each additional allele 
variant. However, variants for this SNP are un-
common (minor allele frequency = 0.2%) and 
the association between this SNP and mortality 
did not remain significant when terms for clini-
cal characteristics were added to the covariate-
adjusted model (Table 2). No significant gene 
level associations were observed (all 
pgene>0.51). Adjustment for debulking status 
and restricting to grade 3 ovarian cancer did not 
influence the results (data not shown). 
 
When histology-specific associations were ex-
amined no significant associations between any 
of the telomere maintenance SNPs and death 
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were observed in those with serous tumors, the 
largest histologic subgroup (data not shown). In 
addition, we observed no substantive differ-
ences in the association between any of the 
SNPs and survival for women with serous tu-
mors when we excluded 47 cases with low-
grade tumors (data not shown). A suggestion of 
heterogeneity between the subtypes was ob-
served for TNKS SNPs rs6982126 
(p h e t e r o g e n e i t y =0 .04)  and rs1545827 
(pheterogeneity=0.03). Among those with mucinous 
tumors, SNP rs6982126 was inversely associ-
ated with death (HR=0.12; 95% CI 0.02-0.88) 
while SNP rs1545827 was associated with 
death (HR=3.18; 95% CI 1.21-8.32); however, 
these results were based on small numbers (76 
and 78 cases, respectively) and no gene level 
associations were observed. There was no het-
erogeneity between subtypes for any other 
SNPs. No effect modification was observed by 
age, smoking, BMI, or estimated lifetime num-
ber of ovulatory cycles (data not shown). 
 
Among 694 cases who received chemotherapy, 
TERT SNPs rs2736100 and rs2853676 were 
associated with mortality in the covariate-
adjusted analyses (HR=1.18; 95% CI 1.01-1.37 
and HR=1.20; 95% CI 1.03-1.40, respectively) 
but these associations did not meet our signifi-
cance threshold and were attenuated after ad-
Table 1. Characteristics of 1480 invasive epithelial ovarian cancer cases, New England Case Control 
Study, 1992-2008.  
Characteristics  
Follow-up time (years), mean (sd) 7.3 (5.0) 
Age at study entry, mean (sd) 55.8 (11.0) 
OC use, n (%) 732 (49.5) 
OC duration (months), mean (SD)a 54.9 (55.6) 
Parous, n (%) 1036 (70.0) 
Parity, mean (SD)b 2.5 (1.3) 
Tubal ligation, n (%) 192 (13.0) 
BMI (kg/m2), mean (SD) 26.6 (6.3) 
Genital talc use, n (%) 495 (33.5) 
Family history of breast or ovarian cancer, n (%)c 193 (13.0) 
Postmenopausal, n (%) 889 (60.1) 
Hormone replacement therapy use (>3 months), 
n (%)d 
301 (33.9) 
Ever smoker, n (%) 809 (54.7) 
White, n (%) 1480 (100.0) 
Histologic type, n (%)  
  Serous 784 (53.0) 
  Endometrioid 285 (19.3) 
  Clear cell 224 (15.1) 
  Mucinous 84 (5.7) 
  Other 68 (4.6) 
  Undifferentiated 35 (2.4) 
Grade, n (%)  
  G1 200 (13.6) 
  G2 290 (19.7) 
  G3 861 (58.6) 
  Indeterminable/Unknown 108 (7.4) 
  Missing 11 (0.8) 
Optimal debulking, n (%)e  
  Optimally debulked 460 (53.7) 
  Not optimally debulked 66 (7.7) 
  Unknown 331 (38.6) 
aAmong oral contraceptive users. bAmong parous women. cFamily history is defined as first degree relative with ovarian cancer or 
breast cancer. dAmong postmenopausal women. eOnly available for cases diagnosed at Brigham and Women's Hospital or Massa-
chusetts General Hospital. 
 
Telomere genes and ovarian cancer survival 
 
 
256                                                                                             Int J Mol Epidemiol Genet 2012:3(3):252-261 
 Table 2. Hazard ratios and 95% confidence intervals for the association between SNPs in telomere-related genes and death among invasive epithelial ovarian cancer cases, NECC 1992-2008. 
          Covariate-adjusteda Covariate and clinical 
characteristics-
adjustedb 
  
      % successfully 
genotyped 
p HWE 
controls 
Per allele Per allele   
Gene rs number n HR 95% CI HR 95% CI pgenec 
TERT RS2736122 1396 94.3% 0.63 0.95 (0.84-1.08) 0.98 (0.87-1.12) 0.51 
TERT RS2075786 1414 95.5% 0.04 0.97 (0.87-1.09) 0.99 (0.88-1.10)   
TERT RS4246742 1410 95.3% 0.01 0.90 (0.77-1.05) 0.95 (0.81-1.11)   
TERT RS6882077d 766 90.2% 0.90 3.49 (1.11-11.00) 2.06 (0.65-6.53)   
TERT RS4975605 1386 93.6% 0.21 1.10 (0.99-1.22) 1.08 (0.97-1.20)   
TERT RS10069690 1392 94.1% 0.18 1.10 (0.98-1.23) 1.10 (0.98-1.23)   
TERT RS2242652d 786 92.6% 0.95 1.08 (0.92-1.27) 1.07 (0.91-1.26)   
TERT RS2736100 1388 93.8% 0.95 1.02 (0.92-1.14) 1.02 (0.91-1.13)   
TERT RS2853676 1415 95.6% 0.60 1.12 (1.00-1.26) 1.12 (1.00-1.26)   
TERT RS2736098 1397 94.4% 0.59 1.01 (0.90-1.14) 1.03 (0.92-1.16)   
TERT RS7726159d 611 96.8% 0.23 1.00 (0.83-1.20) 1.06 (0.89-1.27)   
TRF2 RS251796 1419 95.9% 0.01 1.12 (1.00-1.26) 1.11 (0.99-1.25) 0.61 
TRF2 RS153045 1415 95.6% 0.01 1.04 (0.93-1.16) 1.03 (0.92-1.15)   
TRF2 RS3785074 1417 95.7% 0.55 0.96 (0.85-1.09) 0.96 (0.85-1.09)   
TRF2 RS166134d 790 93.1% 0.63 1.25 (0.74-2.09) 0.96 (0.57-1.62)   
TRF2 RS8061382d 782 92.1% 0.35 0.73 (0.48-1.11) 0.88 (0.58-1.36)   
TRF1 RS2975842 1412 95.4% 0.96 1.00 (0.90-1.12) 0.99 (0.89-1.11) 0.73 
TRF1 RS2975852 1425 96.3% 0.66 0.96 (0.85-1.07) 0.97 (0.86-1.09)   
TRF1 RS6989159d 795 93.6% 0.83 0.18 (0.03-1.29) 0.32 (0.05-2.33)   
TRF1 RS6989493d 799 94.1% 0.93 0.56 (0.18-1.76) 0.85 (0.27-2.70)   
TRF1 RS12334686 1411 95.3% 0.18 0.96 (0.86-1.07) 0.98 (0.88-1.10)   
TRF1 RS6982126 1391 94.0% 0.44 1.04 (0.92-1.18) 1.03 (0.92-1.17)   
TRF1 RS2981096d 795 93.6% 0.11 1.01 (0.73-1.40) 0.98 (0.70-1.36)   
TRF1 RS10107605 1391 94.0% 0.29 1.11 (0.94-1.31) 1.05 (0.89-1.10)   
TRF1 RS1545827 1421 96.0% 0.60 0.99 (0.89-1.10) 0.99 (0.89-1.10)   
TNKS RS1539041 1386 93.6% 0.20 0.91 (0.81-1.03) 0.93 (0.83-1.06) 0.60 
TNKS RS3802650 1413 95.5% 0.80 1.03 (0.92-1.14) 1.04 (0.94-1.16)   
TNKS RS10509637 1397 94.4% 0.32 1.13 (0.97-1.31) 1.11 (0.95-1.29)   
TNKS RS1772180 1420 95.9% 0.34 0.98 (0.88-1.09) 0.98 (0.88-1.09)   
TNKS RS10509639 1425 96.3% 0.11 1.00 (0.83-1.20) 0.99 (0.82-1.19)   
TNKS RS1772186 1383 93.4% 0.68 1.09 (0.94-1.27) 1.05 (0.90-1.23)   
TNKS RS10881982d 787 92.7% 0.88 0.76 (0.50-1.17) 0.84 (0.55-1.30)   
TNKS RS12412538 1411 95.3% 0.65 1.02 (0.90-1.14) 1.03 (0.91-1.15)   
TNKS RS7087365 1428 96.5% 0.84 0.96 (0.86-1.08) 0.98 (0.87-1.10)   
POT1 RS929365 1371 92.6% 0.92 1.00 (0.79-1.27) 1.02 (0.80-1.29) 0.63 
POT1 RS7801661 1374 92.8% 0.41 0.98 (0.87-1.10) 1.03 (0.91-1.17)   
POT1 RS11972248 1402 94.7% 0.52 1.01 (0.88-1.16) 1.03 (0.90-1.18)   
POT1 RS12532038 1412 95.4% 0.35 0.98 (0.87-1.10) 0.96 (0.86-1.08)   
POT1 RS4360236 1403 94.8% 0.17 0.94 (0.78-1.12) 0.89 (0.75-1.06)   
POT1 RS2896361 1382 93.4% 0.12 1.01 (0.91-1.13) 0.97 (0.87-1.09)   
aAdjusted for age (continuous), enrollment phase (1992-1997, 1998-2002, 2003-2008), study center (Massachusetts, New 
Hampshire), tubal ligation (yes, no), smoking (never, former/current), OC use (never, <2 years, 2-5 years, 5+ years), hormone re-
placement therapy (ever use, never), menopausal status (premenopausal/dubious, postmenopausal). All analyses are restricted to 
white women. bAdjusted for covariates above plus histology (serous invasive, mucinous, endometrioid, clear cell, other/
undifferentiated) and grade (1/2, 3, missing/unknown/indeterminable). cPrincipal components analyses were used to determine 
gene-level associations with survival accounting for linkage disequilibrium between SNPs. dRS6882077, RS2242652, RS166134, 
RS8061382, RS6989159, RS6989493, RS2981096, RS10881982 were not genotyped in phase 3 and RS7726159 was not 
genotyped in phases 1 and 2. 
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justment for clinical characteristics (HR=1.13; 
95% CI 0.97-1.31 and HR=1.14; 95% CI 0.98-
1.34). Similar associations with TERT SNPs 
rs2736100 and rs2853676 were observed 
among those receiving carboplatin/cisplatin 
(rs2736100 covariate and clinical characteris-
tics-adjusted HR=1.18; 95% CI 1.01-1.38 and 
rs2853676 covariate and clinical characteris-
tics-adjusted HR=1.16; 95% CI 0.99-1.36). Addi-
tional analyses suggested TERT SNPs 
rs2736100 and rs2075786 and POT1 SNP 
rs7801661, may be relevant to survival among 
women receiving taxol/paclitaxel (Table 3). 
 
Among women who received and had data avail-
able on timing of first-line chemotherapy, those 
with the rs2853676 (covariate-adjusted 
HR=1.30, 95% CI=1.10-1.54) were at risk of 
earlier relapse than women without this poly-
morphism. Furthermore, rs2853676 was asso-
ciated with a 38% increase in risk of relapse 
within 6 months of completing first-line chemo-
therapy (95% CI 1.01-1.88). No association was 
observed between any SNPs and chemo-
refractory disease defined as relapse within six 
months after primary debulking surgery.  
 
Discussion 
 
We observed no significant associations be-
tween SNPs in telomere maintenance genes 
and mortality among this cohort of invasive 
epithelial ovarian cancer cases. To our knowl-
edge we are the first study to examine SNPs on 
telomere maintenance genes in relation to ovar-
ian cancer survival. Previous studies have sug-
gested that TERT SNPs may be associated with 
risk of ovarian cancer and other cancers [10-14, 
16, 18, 24]. However, we did not observe any 
significant associations in our analyses with 
TERT SNPs or SNPs in other telomere mainte-
nance genes (TRF2, TRF1, TNKS, or POT1) after 
accounting for multiple comparisons. In addi-
tion, we observed suggestive associations 
among women who received carboplatin/
cisplatin and taxol/paclitaxel; however, power 
was limited in these subgroups.  
 
Epidemiologic studies suggest risk factors vary 
by histologic type, particularly mucinous vs. non-
mucinous [25-27]. Some genetic studies sug-
gest that genetic susceptibility to ovarian cancer 
may also vary by histologic subtype [28]. Our 
histology specific analyses suggested histologic 
differences in genetic polymorphisms as SNPs 
on the TNKS gene were related to survival only 
in women with mucinous tumors which most 
closely resemble tumors of the gastrointestinal 
tract [29], and in some cases may be metas-
tatic tumors from the gastrointestinal tract [30]. 
The enzyme Tankyrase-1, coded by the TNKS 
gene, regulates telomere length and is down-
regulated in colon tumors [31]. Among colon 
cancer cases, lower Tankyrase-1 mRNA expres-
sion has been associated with reduced colon 
cancer survival [32].  
 
Limitations of our study need to be considered. 
The most aggressive cases of ovarian cancer 
will likely be underrepresented in our study as 
some of these cases will die before enrollment 
while women who survive longer will be more 
likely to enroll. Therefore, if a particular SNP 
predisposes to the most aggressive cases we 
may miss this association. In addition, while our 
results were largely null, important associations 
could have been missed due to limited power in 
subgroup analyses and the omission of SNPs in 
the TERC gene, which have been identified in 
recent studies in relation to telomere length [33
-35] and colorectal cancer incidence [34].  
 
Our study has several strengths. To our knowl-
edge, this is the first study to examine the rela-
tion between SNPs on telomere maintenance 
genes and ovarian cancer survival and relapse. 
We also have genotype data on 1,480 cases 
and detailed information on important clinical 
characteristics, predictors of telomere length, 
and ovarian cancer risk factors. Furthermore, 
we are unlikely to have confounding by ethnicity 
since the study population was limited to Cauca-
sians.  
 
In conclusion, our analyses showed no associa-
tions between polymorphisms on five telomere 
maintenance genes (TERT, TRF2, TRF1, TNKS, 
and POT1) and ovarian cancer survival. Future 
studies with larger populations as well as those 
that examine the TERC gene may further our 
understanding of what role telomeres play in 
ovarian cancer survival.  
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Table 3. Hazard ratios and 95% confidence intervals for the association between SNPs in the TERT gene and death among invasive epithelial ovarian 
cancer cases who received chemotherapy, NECC 1992-2008. 
  Any chemotherapy (n=694 cases) Carboplatin or cisplatin (n=633 cases) Taxol/paclitaxel (n=551 cases) 
  Covariate-adjusteda Covariate and clinical 
characteristics-adjustedb 
Covariate-adjusteda Covariate and clinical 
characteristics-adjustedb 
Covariate-adjusteda Covariate and clinical 
characteristics-adjustedb 
  Per allele Per allele Per allele Per allele Per allele Per allele 
Gene rs number HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
TERT RS2736122 0.93 (0.78-1.12) 0.95 (0.79-1.14) 0.97 (0.81-1.17) 1.00 (0.83-1.20) 0.91 (0.74-1.10) 0.91 (0.75-1.12) 
TERT RS2075786 1.09 (0.93-1.27) 1.16 (0.99-1.36) 1.07 (0.91-1.26) 1.13 (0.96-1.33) 1.15 (0.97-1.36) 1.25 (1.05-1.48) 
TERT RS4246742 0.94 (0.76-1.16) 1.07 (0.86-1.32) 0.97 (0.78-1.20) 1.11 (0.89-1.38) 0.94 (0.75-1.19) 1.05 (0.82-1.33) 
TERT RS6882077c 1.90 (0.46-7.82) 1.28 (0.31-5.31) 1.71 (0.23-12.67) 1.21 (0.16-9.03) 1.47 (0.19-1.12) 1.17 (0.15-8.86) 
TERT RS4975605 1.12 (0.96-1.29) 1.08 (0.94-1.25) 1.12 (0.96-1.30) 1.11 (0.95-1.29) 1.06 (0.90-1.25) 1.09 (0.93-1.28) 
TERT RS10069690 1.15 (0.97-1.35) 1.11 (0.94-1.31) 1.12 (0.94-1.33) 1.08 (0.91-1.28) 1.06 (0.88-1.27) 1.02 (0.85-1.23) 
TERT RS2242652c 1.17 (0.93-1.47) 1.17 (0.93-1.47) 1.14 (0.89-1.45) 1.14 (0.89-1.45) 0.98 (0.73-1.32) 0.98 (0.72-1.33) 
TERT RS2736100 1.18 (1.01-1.37) 1.13 (0.97-1.31) 1.22 (1.04-1.43) 1.18 (1.01-1.38) 1.20 (1.01-1.43) 1.16 (0.97-1.37) 
TERT RS2853676 1.20 (1.03-1.40) 1.14 (0.98-1.34) 1.21 (1.03-1.42) 1.16 (0.99-1.36) 1.15 (0.97-1.37) 1.08 (0.91-1.28) 
TERT RS2736098 1.06 (0.90-1.25) 1.10 (0.93-1.30) 1.07 (0.91-1.27) 1.13 (0.95-1.34) 1.11 (0.93-1.34) 1.18 (0.98-1.42) 
TERT RS7726159c 1.00 (0.79-1.27) 1.09 (0.86-1.37) 1.04 (0.82-1.33) 1.14 (0.89-1.44) 1.01 (0.80-1.29) 1.10 (0.86-1.39) 
pgened  0.07   0.13   0.06   0.06   0.11   0.12   
aAdjusted for age (continuous), enrollment phase (1, 2, 3), study center (Massachusetts, New Hampshire), tubal ligation (yes, no), smoking (never, former/current), OC use (never, <2 years, 2-5 
years, 5+ years), hormone replacement therapy (ever use, never), menopausal status (premenopausal/dubious, postmenopausal). All analyses are restricted to white women. bAdjusted for 
covariates above plus histology (serous invasive, mucinous, endometrioid, clear cell, other/undifferentiated) and grade (1/2, 3, missing/unknown/indeterminable). cRS6882077 and 
RS2242652 were not genotyped in phase 3 and RS7726159 was not genotyped in phases 1 and 2. dPrincipal components analyses were used to determine gene-level associations with 
survival accounting for linkage disequilibrium between SNPS SNPs. 
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